Stason W B
J Hypertens Suppl. 1987 Feb;5(1):S55-9.
Hypertension is a pervasive public health problem with enormous economic as well as medical consequences. Progress in developing more effective, safer and more convenient medications has been remarkable. Similarly, progress in focusing public and professional attention on hypertension has led to earlier treatment and undoubtedly contributed significantly to reduced stroke and cardiovascular mortality rates. Challenges in the next decade will be to resolve residual uncertainties about the balance of benefits and risk of treatment in mild diastolic hypertension and isolated systolic hypertension, and to develop incentives for maximizing the cost-effectiveness of treatment in those for whom treatment is, on balance, beneficial. Quality-of-life parameters will play prominent roles in clinical and policy decisions with respect to each of these challenges.
高血压是一个普遍存在的公共卫生问题，会产生巨大的经济和医学后果。在研发更有效、更安全、更便捷药物方面已取得显著进展。同样，在使公众和专业人士关注高血压方面所取得的进展促使了更早治疗，无疑对降低中风和心血管疾病死亡率做出了重大贡献。未来十年的挑战将是解决轻度舒张期高血压和单纯收缩期高血压治疗中效益与风险平衡方面尚存的不确定性，并制定激励措施，以在总体上治疗有益的人群中最大限度地提高治疗的成本效益。生活质量参数将在应对上述每一项挑战的临床和政策决策中发挥重要作用。
